# Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

> clinical trial · VERIFIED · 2026-08-06

Status: RECRUITING · Sponsor: Greenwich LifeSciences, Inc. · Condition: Breast Cancer

- Company: Greenwich LifeSciences, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05232916

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.